The business combination was announced August 4, 2022 and will create a leading advanced cell therapy CDMO offering process development expertise and cGMP manufacturing for a broad range of autologous and allogeneic cell therapies, with unparalleled expertise in gene editing and industry-leading induced Pluripotent Stem Cell (iPSC) capabilities.
McDermott also represented WindRose in two additional recent transactions, including the debt financing and recapitalization of RevHealth, one of the largest independent providers of omnichannel healthcare communications to the life sciences industry; and its strategic investment in Brown Parker & DeMarinis Advertising, Inc., LLC, a hospital- and health system-focused provider of data-driven marketing solutions.
Read Lykan Biosciences and RoslinCT’s combined press release here.
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.